The European Commission (EC) has approved Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for adult patients with moderately to severely active Crohn’s disease.  The approval is based on data which showed that guselkumab induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!